From theheart.org on Medscape

Coverage from the

American Heart Association (AHA) Scientific Sessions 2024

November 16 - 18, 2024; Chicago, Illinois

November 16 - 18, 2024 Chicago, Illinois

Conference News

AHA 2024 Soaring Pacemaker Demand Spurs Controversial New Approach
Medscape Medical News, December 23, 2024
AHA 2024 Better Amyloidosis Treatments Expand Options and Cures
Medscape Medical News, December 6, 2024
AHA 2024 Nasal Spray Diuretic Evades Heart Failure Drug Flaw
Medscape Medical News, December 4, 2024
AHA 2024 Flu Shot Reminders Improve Use in Heart Attack Survivors
Medscape Medical News, December 4, 2024
AHA 2024 Cognitive Decline in AF Not Reduced by Anticoagulation
Medscape Medical News, December 2, 2024
AHA 2024 Anticoagulant Considered After Bioprosthetic Valve Surgery
Medscape Medical News, November 25, 2024
AHA 2024 PVI Add-Ons Provide Better Control of Persistent AF
Medscape Medical News, November 22, 2024
AHA 2024 For AF, LAA Rivals Anticoagulants After Ablation
Medscape Medical News, November 20, 2024
AHA 2024 Spironolactone Shows Mixed Results in Acute MI
Medscape Medical News, November 19, 2024

AHA 2024 Wearable Device Can Warn of Worsening Heart Failure
Medscape Medical News, November 19, 2024
AHA 2024 Common Heart Failure Drugs Ease Heart Damage During Chemo
Medscape Medical News, November 19, 2024
AHA 2024 New Pill Successfully Lowers Lp(a) Levels
Medscape Medical News, November 19, 2024
AHA 2024 New Trial Result Pushes Past Antiarrhythmic Therapy After MI
Medscape Medical News, November 18, 2024
AHA 2024 Any Hypertension Drug Combo Can Work in Underserved Groups
Medscape Medical News, November 18, 2024
AHA 2024 Reconditioned Pacemakers Expand Access
Medscape Medical News, November 17, 2024
AHA 2024 AI Makes Echocardiography Faster, More Accessible
Medscape Medical News, November 17, 2024
AHA 2024 Intense Blood Pressure Lowering Benefit Confirmed in Diabetes
Medscape Medical News, November 17, 2024
AHA 2024 Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
Medscape Medical News, November 16, 2024

Perspectives

Drugs to Target Lp(a): What’s Coming
Michelle L. O'Donoghue, MD, MPH; Stephen J. Nicholls, MBBS, PhD
Does STEMI Need a Rebrand to ‘Occlusion MI’?
Robert A. Harrington, MD; Manesh R. Patel, MD; C. Michael Gibson, MD
Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT?
John M. Mandrola, MD
REALIZE-K: A New Potassium Binder to Help Keep Spiro on Board
Ileana L. Piña, MD, MPH
Heart Failure GDMT: Could Pharmacists Be the Fifth Pillar?
Ileana L. Piña, MD, MPH; Alexander T. Sandhu, MD, MS
Colchicine or MRA Post-MI: No CLEAR Benefit
Michelle L. O'Donoghue, MD, MPH; Sanjit S. Jolly, MD, MSc
The Most Worrisome Study at AHA 2024
John M. Mandrola, MD
4 Reasons to Question Percutaneous LAAC After AF Ablation
John M. Mandrola, MD

Popular News From AHA 2023

In MI With Anemia, Results May Favor Liberal Transfusion Although the primary outcome was not statistically different between a liberal and more restrictive transfusion strategy, secondary results suggest some advantages for the liberal approach.
Medscape Medical News, Nov 11, 2023
Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.
Medscape Medical News, Nov 11, 2023
Blood Pressure Lowering Reduces Dementia Risk Blood Pressure Lowering Reduces Dementia Risk
Medscape Medical News, Nov 12, 2023

Previous Coverage

Related Resources

All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.